A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
Clinical trial NCT06492616 · RECRUITING
Trial details
- NCT number
- NCT06492616
- Sponsor
- Stemline Therapeutics, Inc.
- Status
- RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2024-09-27
- Primary completion
- 2029-08-01
- Enrollment
- 4220
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.